While researching another topic, I came across this from 1998, Effects of vaccine on pain and fatigue in patients with fibromyalgia/chronic fatigue syndrome. This is logical (just need the RIGHT vaccine) from observations made in my last post.
” Significant improvement was seen in seven of the 15 CPRS items in the vaccine group when pretreatment values were compared to post-treatment values. In CPRS <<fatiguability>>, there were significant intergroup differences, and in CPRS <<pain>> intergroup differences bordered on significance…. In a follow-up study of 23 patients, thevaccine treatment was continued for 2-6 years. Fifty percent were rehabilitated successfully and resumed half-time or full-time work.”
This was followed up with a 2002 study. ” The treatment was well tolerated. Intention-to-treat analysis showed 32/49 (65%) responders in the SB(vaccine) group compared to 9/49 (18%) in the placebo group (P<0.001). … An increase in CPRS symptoms at withdrawal was noted in the SB group. In conclusion, treatment with staphylococcus toxoid injections over 6 months led to significant improvement in patients with FM and CFS. Maintenance treatment is required to prevent relapse.” [2002]
“One hundred and sixty patients with Fibromyalgia and Chronic Fatigue Syndrome, who were on a continuous treatment with a Staphylococcus vaccine, were followed during one year with repeated consultation visits…. showed improvement from start of treatment and also further improvement during the follow-up year. In view of the natural history for these disorders the result is of interest.”[2006 article in Journal of Chronic Fatigue]
Discussion from 2010 on Phoenix Rising.
BENEFITS OF VACCINE FOR ANTIBIOTIC RESISTANT STAPHYLOCOCCUS AUREUS:
- Polyvalent vaccine targets antibiotic resistant strains of S. aureus
- Provides protection against the most common strains of S. aureus
- Targets toxins secreted from S. aureus
- Mechanism of action targets surface proteins
The vaccine is available for veterinary use.
Bottom Line
It is worth while for a researcher to explore producing a series of vaccines for overgrowth species/strains in CFS/FM. It may be possible to do this with a similar method as was used in the 1930’s (i.e. not high tech). The 50% success rate seen in multiple studies is in line with a microbiome dysfunction that is multiple species — thus any single item will likely only be partially effective.
Recent literature and reports on the vaccine itself (National Institute of….):
- Where does a Staphylococcus aureus vaccine stand? [2014]
- Overcoming Challenges in Staphylococcus aureus Vaccine Development [June 2013]
Fast Track Clinical Trials (not for CFS):
CFS Remission 